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e26 Surgical Trainee Poster AbstractsMethods: A prospective anonymous online survey was
administered to members of the Society for Clinical
Vascular Surgery (SCVS) and the Vascular Surgical Society of
Great Britain and Ireland (VSS). Each member evaluated
general and procedural speciﬁc complications for both
arterial and venous interventions. Greater than 75%
reporting for a speciﬁc complication was deemed the
threshold for consensus opinion.
Results: Overall response rate was 24.8%. The majority of
respondents were attending surgeons (81.5% SCVS vs.
85.2% VSS). Both societies considered senior trainees
competent to obtain consent. The majority of patients were
consented primarily by the attending (67.6% SCVS vs. 90.6%
VSS, p<0.01) on a pre-printed consent form (95.1% SCVS vs.
98.7% VSS). Consent was obtained on the day of surgery in
the ofﬁce (35.4%-SCVS) or the day before surgery in the
hospital ward (35.1%-VSS) with the provision of additional
written documentation (59.2% SCVS vs. 85.4% VSS,
p<0.01). Both societies concurred with documentation of
general complications including bleeding, cardiac, cerebro-
vascular, respiratory, thromboembolic and wound infection
as well as more speciﬁc complications pertaining to aortic
aneurysm, carotid endarterectomy, lower limb bypass,
amputation and venous surgeries. Although the VSS re-
ported a signiﬁcantly higher consent training rate (14.1%
SCVS vs. 40.8% VSS, p<0.01), both societies stated this
mainly involved ad-hoc informal training.
Conclusion: Whilst completion logistics of vascular consent
vary, both SCVS and VSS members concur on the majority of
complications necessary for inclusion in informed vascular
consent.
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Background: Inferior vena cava thrombosis (IVCT) remains
rare with an incidence of 0.4%. We describe our initial
experience with ultrasonic accelerated thrombolysis (UAT)
of IVCT.
Methods: All patients diagnosed with symptomatic IVCT
who were treated with UAT from January 2012 to August
2013 were included. Patient data regarding clinical pre-
sentation, thromboembolic risk factors, pertinent imaging,
treatment pathway and clinical outcome were recorded.
Results: Seven patients (5 males, 2 females, mean age 58.1
years) presented with lower extremity DVT. Four patients
had a history of neoplastic disease and two were current
smokers. Four patients had a history of previous DVT and 6
patients a history of pulmonary emboli. All seven patientswere previously anticoagulated and had IVC ﬁlters in-situ.
Pro-thrombotic haematological analyses were negative for
all patients. Ultrasound duplex imaging identiﬁed proximal
lower extremity thrombus in four patients (57%) while
cross-sectional imaging conﬁrmed thrombus extending
from the iliac veins into the IVC in all seven patients. All
patients were initially treated with limb elevation,
compression hosiery and systemic heparinisation. Signiﬁ-
cantly symptomatic patients proceeded to venography and
evaluation of clot burden. The thrombus was crossed and
bilateral UAT catheters were placed extending into the su-
prarenal IVC. Combined infusions were commenced of
0.5mg tissue plasminogen activator and 35mls of normal
saline coolant via the UAT catheters and 500IU of heparin
via the 7-Fr sheath per hour to each limb separately. After
twenty-four hours, repeat venography was satisfactory in
one patient. The remaining six patients required mechanical
thrombectomy and balloon angioplasty if necessary, which
resulted in satisfactory ﬂow in ﬁve patients. The remaining
patient required an additional twenty-four hour UAT infu-
sion followed by further mechanical thrombectomy before
satisfactory ﬂow was obtained. All patients are currently
well and remain anticoagulated (warfarin ¼ 6,
rivaroxaban ¼ 1) with improvement in lower extremity
symptomatology and no recurrence of IVCT (mean follow-
up 7.6, range 1e20 months).
Conclusions: This is the ﬁrst reported series of UAT for IVCT.
These early results suggest this modality may be helpful in
treating patients with large IVC thrombus burden and sig-
niﬁcant clinical symptoms with successful clot dissolution
and satisfactory venous ﬂow without signiﬁcant patient
distress or complications.
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Introduction, Aims and Methods: At present there does not
appear to be an agreed best practice for management of
expanding type 2 endoleaks following EVAR. Endovascular
coiling seems to be the most prominent in recent years.
With new methods becoming available we aim to review
the outcomes for current practice.
A retrospective case note review of 18 patients was un-
dertaken. PACS, electronic care records & GP notes were
used to assess progression in sac dimension & clinical health.
Results: 88% (16/18) underwent embolization as a deﬁni-
tive procedure. 3 patients died following rupture of AAA
whilst a further 9 died from medical co-morbidities. Mean
time to death in ruptures in these patients was 22 months
vs 49 months in non-ruptured. Sac size on latest scan was
larger in ruptured group (114mm vs 77mm). There was also
on average less interventions on ruptured group (1 vs 1.7).
Mean survival of the remaining 6 patients is 72 months
(43e105) with an average sac size of 60mm.
